Ultragenyx Analyst Day Presentation slide image

Ultragenyx Analyst Day Presentation

DOJOLVIⓇ Exclusivity summary United States DOJOLVI TRIHEPTANOIN Oral Liquid NCE Exclusivity LC-FAOD Orphan Exclusivity Dojolvi COM Patent Ultrapure Dojolvi (Pending) 2025 2027 2029* 2034 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 Europe *Includes projected US PTE award 23 Confidential and Proprietary 2034 Ultrapure Dojolvi (Pending) ultragenyx
View entire presentation